Risk factors that may be driving the emergence of drug resistance in tuberculosis patients treated in Yangon, Myanmar
暂无分享,去创建一个
[1] L. Westerkamp,et al. Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness , 2015, BMC Infectious Diseases.
[2] R. Coker,et al. How to hinder tuberculosis control: five easy steps , 2014, The Lancet.
[3] Tuberculosis in Myanmar Progress , Plans and Challenges , 2012 .
[4] A. Harries,et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review , 2011, BMC medicine.
[5] I. Hazarika. Role of Private Sector in Providing Tuberculosis Care: Evidence from a Population-based Survey in India , 2011, Journal of global infectious diseases.
[6] Philippe Glaziou,et al. Tuberculosis control and elimination 2010–50: cure, care, and social development , 2010, The Lancet.
[7] J. Caminero. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] S. Saw,et al. Success and challenges of Public-Private Mix DOTS initiatives in Myanmar: a process evaluation for partnership approach of non-governmental organizations. , 2009 .
[9] P. Garner,et al. Directly observed therapy for treating tuberculosis. , 2015, The Cochrane database of systematic reviews.
[10] M. Uplekar,et al. Social franchising of TB care through private GPs in Myanmar: an assessment of treatment results, access, equity and financial protection. , 2007, Health policy and planning.
[11] Ross Upshur,et al. XDR-TB in South Africa: No Time for Denial or Complacency , 2007, PLoS medicine.
[12] S. Ramaiah,et al. Private health care in developing countries , 2002, BMJ : British Medical Journal.
[13] S. Saw,et al. Existing practices of general practitioners on diagnosis and treatment of tuberculosis in Yangon , 2002 .
[14] Vikram Pathania,et al. Private practitioners and public health: weak links in tuberculosis control , 2001, The Lancet.
[15] G. Tomson,et al. “Doi moi” and private pharmacies: a case study on dispensing and financial issues in Hanoi, Vietnam , 1999, European Journal of Clinical Pharmacology.
[16] Y. Amdekar,et al. Multidrug resistant tuberculosis. , 1998, Indian pediatrics.
[17] M. Uplekar,et al. Treatment of tuberculosis by private general practitioners in India. , 1991, Tubercle.
[18] C. Dolea,et al. World Health Organization , 1949, International Organization.